目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T68663 | |||
GPI-15427 is a potent PARP-1 inhibitor capable of crossing the blood-brain barrier, which can significantly increased the antitumor activity of the methylating agent TMZ against malignant melanoma, glioblastoma multiforme, or lymphoma growing at the CNS site. GPI-15427 acts as a potent inhibitor of the enzyme, being capable of inhibiting the activity of purified PARP-1 at nanomolar concentrations. GPI-15427 induced significant sensitization to radiotherapy, representing a promising new treatment in the management of HNSCC. | |||
T81389 | |||
Properdistatin是一种衍生自thrombospondin-1 (TSP-1)结构域的小分子肽,其作用机制主要在于抑制血管生成并促进血管功能的改善,因此在黑色素瘤的研究中显示出应用潜力。 | |||
T27614 | |||
INU-152 is a pan-RAF inhibitor. INU-152 has potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer. INU-152 inhibits all RAF isoforms and inhibits MAPK pathways in mutant BRAF cells. INU-152 exhibits minimal paradoxical pathway activa | |||
TN4471 | IL Receptor Antifection | ||
Lysicamine shows significant antioxidant capacity in the ORAC(FL) assay and it is active against S. epidermidis and C. dubliniensis, with MIC values in the range 12.5-100 microg mL(-1). Lysicamine has antimicrobial and anti-inflammation activity, the mini | |||
T35613 | |||
Cytostatin (sodium salt) is a natural antitumor inhibitor of cell adhesion to extracellular matrix, blocking adhesion of B16 melanoma cells to laminin and collagen type IV in vitro (IC50s = 1.3 and 1.4 μg/ml, respectively) and B16 cells metastatic activity in mice. It induces apoptosis of FS3 mouse fibrosarcoma cells (IC50 = 3.1 μg/ml). Cytostatin (sodium salt) potently and selectively inhibits protein phosphatase 2A (PP2A; IC50 = 29 nM against the catalytic subunit), while having no effect against PP1, PP2B, or PP5. | |||
T79366 | HDAC | ||
SP-2-225为选择性HDAC6抑制剂,能增强T细胞交叉呈递的癌症相关抗原以及促进巨噬细胞抗原产生。此化合物亦可缩减同基因SM1黑色素瘤模型的肿瘤体积。 | |||
T37722 | |||
Diprovocim-1 is an agonist of the toll-like receptor 1/2 heterodimer.1It induces TNF-α release in THP-1 cells (EC50= 110 pM), an effect that can be inhibited by anti-TLR1 or anti-TLR2 antibodies. Diprovocim-1 (10 mg/kg) increases the production of ovalbumin-specific IgG1 in wild-type, but notTLR2-/-, mice sensitized to ovalbumin.2It also enhances anti-PD-L1 antibody-induced activation of cytotoxic T lymphocytes, reduction of tumor growth, and increases in survival in a B16/F10 murine melanoma model. 1.Morin, M.D., Wang, Y., Jones, B.T., et al.Diprovocims: A new and exceptionally potent class of toll-like receptor agonistsJ. Am. Chem. Soc.140(43)14440-14454(2018) 2.Wang, Y., Su, L., Morin, M.D., et al.Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in miceProc. Natl. Acad. Sci. U.S.A.115(37)E8698-E8706(2018) | |||
T83344 | |||
3-O-β-D-Glucopyranosyl(1→2)-[a-Lrhamnopyranosyl(1→3)]-β-D-glucopyranosyl 28-O-β-D-glucuronopyranoside 是Polaskia chichipeBackbg 中分离的一种皂苷,具有抑制B16黑色素瘤细胞中黑色素生物合成的活性,100 μM 浓度可达到84.2%的抑制效果。 | |||
T36138 | |||
BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM). It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis. | |||
T72009 | |||
N-Phenylthiourea is a tyrosinase inhibitor and building block. It increases the susceptibility of SK-MEL-188 melanoma cells in melanogenesis-inducing conditions to γ-radiation-induced cytotoxicity when used at a concentration of 0.01 μM. N-Phenylthiourea has been used as a precursor in the synthesis of compounds with antibacterial and antifungal activities. It has also been used as a genetic marker for taste because only some people detect it as a bitter taste. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-01137 | MIA Protein, Human, Recombinant (His) | Human | E. coli | ||
Melanoma Inhibitory Activity Protein (MIA) is an autocrine growth regulatory protein secreted from chondrocytes and malignant melanoma cells, which was the first discovered member of a family of secreted cytokines termed the MIA/OTOR family. The four known members of this family: MIA, MIA2, OTOR and TANGO each contain a Src homology-3 (SH3)-like domain. MIA acts as a potent tumor cell growth inhibitor for malignant melanoma cells and some other neuroectodermal tumors, including gliomas, in an autocrine fashion and promotes melanoma metastasis by binding competitively to fibronectin and laminin in a manner that results in melanoma cell detachment from the extracellular matrix in vivo. The protein MIA has been shown to represent a very sensitive and specific serum marker for systemic malignant melanoma that might be useful for staging of primary melanomas, detection of progression from localized to metastatic disease during follow-up, and monitoring therapy of advanced melanomas. Elevated levels of MIA may represent a clinically useful marker for diagnosis of melanoma metastasis as well as a potential marker for rheumatoid arthritis.
|
|||||
TMPY-01775 | AIM2 Protein, Human, Recombinant (GST) | Human | Baculovirus Insect Cells | ||
AIM2, Absent In Melanoma 2 is a member of the interferon-inducible HIN-200 protein family that contains an amino-terminal pyrin domain and a carboxy-terminal oligonucleotide/oligosaccharide-binding domain, senses cytoplasmic DNA by means of its oligonucleotide/oligosaccharide-binding domain and interacts with ASC (apoptosis-associated speck-like protein containing a CARD) through its pyrin domain to activate caspase-1. In response to foreign cytoplasmic DNA, AIM2 forms an inflammasome, resulting in caspase activation in inflammatory cells. It had been pointed to a role of AIM2 function in both inflammation and cancer. AIM-2 antigen is expressed in a wide variety of tumor types, including neuroectodermal tumors, as well as breast, ovarian and colon carcinomas. AIM-2 could be used as a tumor antigen target for monitoring vaccine trials or to develop antigen specific active immunotherapy for glioma patients.
|
|||||
TMPY-01034 | CD146/MCAM Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
CD146/MCAM Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 61.3 kDa and the accession number is A0A024R3I5.
|
|||||
TMPY-06064 | CD146/MCAM Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 Cells | ||
CD146/MCAM Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 61.3 kDa and the accession number is A0A024R3I5.
|
|||||
TMPY-00879 | CD146/MCAM Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
CD146/MCAM Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 86.4 kDa and the accession number is A0A024R3I5.
|
|||||
TMPH-01086 | CSPG4 Protein, Human, Recombinant (His & Myc) | Human | HEK293 Cells | ||
CSPG4 Protein, Human, Recombinant (His & Myc) is expressed in HEK293 mammalian cells with N-10xHis and C-Myc tag. The predicted molecular weight is 73.2 kDa and the accession number is Q6UVK1.
|
|||||
TMPY-00008 | CXCL1 Protein, Rat, Recombinant | Rat | E. coli | ||
CXCL1 Protein, Rat, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 7.9 kDa and the accession number is P14095.
|
|||||
TMPK-01495 | HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01493 | HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPY-02502 | CD146/MCAM Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
CD146/MCAM Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 61.3 kDa and the accession number is Q8R2Y2-1.
|
|||||
TMPY-00433 | CXCL1 Protein, Mouse, Recombinant | Mouse | E. coli | ||
CXCL1 Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 8.3 kDa and the accession number is A2RTH0.
|
|||||
TMPK-01472 | HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01473 | HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPY-02026 | CXCL1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
CXCL1 Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with His and SUMO tag. The predicted molecular weight is 21.3 kDa and the accession number is P09341-1.
|
|||||
TMPY-02180 | CXCL1 Protein, Human, Recombinant (His & NusA) | Human | E. coli | ||
CXCL1 Protein, Human, Recombinant (His & NusA) is expressed in E. coli expression system with His and NusA tag. The predicted molecular weight is 65 kDa and the accession number is P09341-1.
|
|||||
TMPY-02868 | CXCL1 Protein, Human, Recombinant | Human | E. coli | ||
CXCL1 Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 7.9 kDa and the accession number is P09341-1.
|
|||||
TMPH-03526 | Cap8A Protein, S. aureus, Recombinant (His) | Staphylococcus aureus | E. coli | ||
May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. Cap8A Protein, S. aureus, Recombinant (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 26.4 kDa and the accession number is O15479.
|
|||||
TMPJ-00011 | CXCL2 Protein, Mouse, Recombinant | Mouse | E. coli | ||
C-X-C motif chemokine 2 (CXCL2,MIP-2) belongs to the intercrine alpha (chemokine CxC) family. It was originally identified as a heparin-binding protein secreted from a murine macrophage cell line in response to endotoxin stimulation. The expression of mouse MIP-2 is stimulated by endotoxin. The mouse MIP-2 shares approximately 63% aa sequence identity with murine KC, another mouse alpha chemokine, which is induced by PDGF. It has been suggested that mouse KC and MIP-2 are the homologs of the human GROs and rat CINCs. Chemotactic for human polymorphonuclear leukocytes but does not induce chemokinesis or an oxidative burst. The expression of MIP-2 was found to be associated with neutrophil influx in pulmonary inflammation and glomerulonephritis, suggesting that MIP-2 may contribute to the pathogenesis of inflammatory diseases.
|
|||||
TMPK-01447 | HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPK-01441 | HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPK-01454 | HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPK-01469 | HLA-A*02:01&B2M&MART-1 (ELAGIGILTV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen recognized by T cell-1 (Mart-1), one of the melanosome-specific proteins, also recognized by cytotoxicity T lymphocytes as a marker. Mart-1 is considered to play a critical role in the immunotherapy for melanoma.
|
|||||
TMPK-01406 | HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 Cells | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPK-01455 | HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPJ-01145 | ABCB5 Protein, Human, Recombinant (Trx) | Human | E. coli | ||
ATP-binding cassette sub-family B member 5(ABCB5) is a plasma membrane-spanning protein. ABCB5 is principally expressed in physiological skin and human malignant melanoma. ABCB5 has been suggested to regulate skin progenitor cell fusion and mediate chemotherapeutic drug resistance in stem-like tumor cell subpopulations in human malignant melanoma. It is commonly over-expressed on circulating melanoma tumour cells. Furthermore, the ABCB5+ melanoma- initiating cells were demonstrated to express FLT1 (VEGFR1) receptor tyrosine kinase which was functionally required for efficient xenograft tumor formation, as demonstrated by shRNA knockdown experiments.
|
|||||
TMPK-01468 | HLA-A*02:01&B2M&MART-1 (ELAGIGILTV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen recognized by T cell-1 (Mart-1), one of the melanosome-specific proteins, also recognized by cytotoxicity T lymphocytes as a marker. Mart-1 is considered to play a critical role in the immunotherapy for melanoma.
|
|||||
TMPH-01656 | MAGEA12 Protein, Human, Recombinant (His & Myc) | Human | E. coli | ||
Not known, though may play a role tumor transformation or progression. In vitro promotes cell viability in melanoma cell lines.
|
|||||
TMPY-04817 | Syntenin Protein, Human, Recombinant (His) | Human | E. coli | ||
Syntenin1/SDCBP (syndecan binding protein), also known as melanoma differentiation associated gene-9 (MDA-9), is a PDZ domain-containing molecule, which was initially identified as a key oncogene in melanoma. IL-6 promotes glioma cell proliferation and invasion by inducing SDCBP expression, which is mediated by JAK2/STAT3 signaling. SDCBP might be an important marker for identifying Triple negative breast cancer (TNBC) cases that are suitable for dasatinib therapy.
|
|||||
TMPK-01474 | HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01459 | HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01.
|
|||||
TMPK-01470 | HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01.
|
|||||
TMPH-01341 | FILIP1L Protein, Human, Recombinant (His) | Human | E. coli | ||
Acts as a regulator of the antiangiogenic activity on endothelial cells. When overexpressed in endothelial cells, leads to inhibition of cell proliferation and migration and an increase in apoptosis. Inhibits melanoma growth When expressed in tumor-associated vasculature. FILIP1L Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 27.6 kDa and the accession number is Q4L180.
|
|||||
TMPH-02507 | Angiogenin-4 Protein, Mouse, Recombinant (His & Myc & SUMO) | Mouse | E. coli | ||
Has bactericidal activity against E.faecalis and L.monocytogenes, but not against L.innocua and E.coli. Promotes angiogenesis (in vitro). Has low ribonuclease activity (in vitro). Promotes proliferation of melanoma cells, but not of endothelial cells or fibroblasts (in vitro). Angiogenin-4 Protein, Mouse, Recombinant (His & Myc & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO and C-Myc tag. The predicted molecular weight is 31.4 kDa and the accession number is Q3TMQ6.
|
|||||
TMPK-01550 | HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and GVYDGREHTV peptide of the MAGE-A4.
|
|||||
TMPK-01524 | HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and GVYDGREHTV peptide of the MAGE-A4.
|
|||||
TMPK-01547 | HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) Complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and GVYDGREHTV peptide of the MAGE-A4.
|
|||||
TMPK-00789 | CD228 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Melanotransferrin is typically overexpressed in melanoma cells compared to other cell types - including cancer cells - and is efficiently sorted and secreted with nanovesicles, or so-called exosomes, due to its membrane-anchoring by a glycosylphosphatidylinositol. Melanotransferrin is exposed on the surface of exosomes and is accessible for antibody recognition.
|
|||||
TMPH-02508 | Angiogenin-4 Protein, Mouse, Recombinant (His & SUMOstar) | Mouse | P. pastoris (Yeast) | ||
Has bactericidal activity against E.faecalis and L.monocytogenes, but not against L.innocua and E.coli. Promotes angiogenesis (in vitro). Has low ribonuclease activity (in vitro). Promotes proliferation of melanoma cells, but not of endothelial cells or fibroblasts (in vitro). Angiogenin-4 Protein, Mouse, Recombinant (His & SUMOstar) is expressed in yeast with N-6xHis-sumostar tag. The predicted molecular weight is 29.9 kDa and the accession number is Q3TMQ6.
|
|||||
TMPH-01654 | MAGEA1 Protein, Human, Recombinant (His) | Human | P. pastoris (Yeast) | ||
May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. MAGEA1 Protein, Human, Recombinant (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 36.3 kDa and the accession number is P43355.
|
|||||
TMPJ-00160 | EMMPRIN/CD147 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) belongs to the immunoglobulin superfamily, which has the homology to both the immunoglobulin V domain and MHC class II antigen β-chain. EMMPRIN is a transmembrane glycoprotein with different forms, resulting from different modes of glycosylation and N-terminal sequence variants. EMMPRIN can be expressed in breast cancer, oral squamous cell carcinoma, glioma, lymphoma, lung, bladder, and melanoma carcinomas cells. EMMPRIN promotes invasion, metastasis, growth, and survival of malignants cells, serves as a receptor for extracellular cyclophilinthe, may play a role in signal transduction.
|
|||||
TMPY-03795 | EIF5A2 Protein, Human, Recombinant (His) | Human | E. coli | ||
Eukaryotic translation initiation factor 5A2 (EIF5A2) has been demonstrated to be upregulated in numerous types of human cancer and is associated with cancer progression. Silencing of EIF5A2 in the NSCLC cells resulted in the downregulation of the tumorigenic proteins, apoptosis regulator Bcl-2 and myc proto-oncogene protein, and upregulation of E-cadherin, suggesting that EIF5A2 promotes proliferation and metastasis through these proteins. EIF5A2 may therefore serve as a novel therapeutic target for the treatment of NSCLC. EIF5A2 might be a novel therapeutic target for the inhibition of NPC progress. EIF5A2 overexpression may contribute to cancer progression and poor prognosis, it could be a novel potential prognostic marker for FIGO stage I-II cervical cancer. EIF5A2 upregulation plays an important oncogenic role in gastric cancer. EIF5A2 may represent a new predictor for poor survival and is a potential therapeutic target for gastric cancer. The eukaryotic initiation factor 5A2 (EIF5A2) over-expression enhances HCC cell metastasis. EIF5A2, as a target of PI3K/Akt, promotes melanoma cell invasion and may serve as a promising prognostic marker and a potential therapeutic target for melanoma.
|
|||||
TMPJ-00764 | Catalase/CAT Protein, Human, Recombinant | Human | E. coli | ||
Catalase (CAT) is a member of the catalase family. It exists as a homotetramer that occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Catalase is localized in the peroxisome. Catalase promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells, and normal and transformed fibroblast cells. Defects in CAT are the cause of acatalasemia which is characterized by absence of catalase activity in red cells and is associated with ulcerating oral lesions.
|
|||||
TMPK-00073 | TDGF1/Cripto Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TDGF1 (CRIPTO) is a member of the epidermal growth factor-Cripto-1/FRL-1/Cryptic (EGF/CFC) gene family and an obligate co-receptor involved in NODAL signaling, a developmental program implicated in midline, forebrain, and left-right axis development in model organisms. Cripto-1 is enriched in a subpopulation of embryonal, melanoma, prostate, and pancreatic cancer cells that possess stem-like characteristics. Therefore, Cripto-1 may play a role during developmental EMT, and it may also be involved in the reprogramming of differentiated tumor cells into cancer stem cells through the induction of an EMT program.
|
|||||
TMPY-02276 | GPR56 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
ADGRG1 (Adhesion G Protein-Coupled Receptor G1, also known as GPR56) is a Protein Coding gene. GPR56 is a member of an adhesion G protein-coupled receptor family with a very long N-terminal stalk and seven transmembrane domains. The encoded protein binds specifically to transglutaminase 2, a component of tissue and tumor stroma implicated as an inhibitor of tumor progression. GPR56 may be a target for the treatment of type 2 diabetes. GPR56 inhibits melanoma metastatic growth by impeding the expansion of micrometastases to macrometastases. GPR56 loss of function promotes mesenchymal differentiation and radioresistance of glioma initiating cells both in vitro and in vivo. Diseases associated with ADGRG1 include Polymicrogyria, Bilateral Frontoparietal, and Polymicrogyria, Bilateral Perisylvian, Autosomal Recessive.
|
|||||
TMPJ-00884 | CXCL9 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Chemokine (C-X-C motif) ligand 9 (CXCL9, MIG), is a small cytokine belonging to the CXC chemokine family. CXCL9 functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. It together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. it plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9, and recipient CD4 lymphocytes are necessary for sustained CXCL9 production and CAV development in this model.
|
|||||
TMPJ-00339 | ALCAM Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
Activated leukocyte cell adhesion molecule (ALCAM), also named as CD166 and MEMD, is a typeI transmembrane glycoprotein of immunoglobulin superfamily, which mediates homotypic and heterotypic interactions between cells. ALCAM interacts with high affinity with CD6 molecule but weaker homotypic (ALCAM–ALCAM) interactions have also been described. ALCAM–CD6 interactions play an important role in the maintenance of T cell activation, proliferation as well as in formation of immune synapse between antigen-presenting cell and lymphocytes. ALCAM is expressed on a wide variety of cells, particularly on activated lymphocytes, dendritic cells and monocytes, and on various epithelial cell types. It is also involved in multiple processes including embryogenesis, hematopoiesis, angiogenesis, and immune response. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells in most adult tissues. Recently studies showed ALCAM has prognostic relevance in several human carcinomas, and it has been used as a biomarker for several tumor entities, including melanoma, gynecologic, urologic, and gastrointestinal cancers.
|
|||||
TMPJ-00990 | S100B Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
S100-B, is an acidic protein with a molecular weight of 21 kDa belonging to the S100 family. S100-B contains two EF-hand-type calcium-binding motifs separated by a hinge region with a hydrophobic cleft. S100-B plays an important role in neurodevelopment, differentiation, and brain construction. S100-B has neuroprotective effects, but at high concentrations S100-B is neurotoxic. Extracellular concentration of S100-B increases following brain damage, which easily penetrates into cerebrospinal fluid in brain damage and then into the blood. S100-B is expressed and produced by astrocytes in vertebrate brains and in the CNS, and the astrocytes are the major cells producing S100-B protein in gray matter, as well as oligodendrocytes are the predominant S100-B in protein producing cells in white matter. The major advantage of using S100-B is that elevations in serum or CSF levels provide a sensitive measure for determining CNS injury at the molecular level before gross changes develop, enabling timely delivery of crucial medical intervention before irreversible damage occurs. In addition, S100-B, which is also present in Mouse melanocytes, is a reliable marker for melanoma malignancy both in bioptic tissue and in serum.
|